The government-funded project is designed to help companies in the biologics market to develop and commercialise new biologics process technologies. Biologics, or biopharmaceuticals, are medicines manufactured using biotechnology, usually involving live organisms such as cells, bacteria or yeast.
CPI has published a contract notice for the design, build, fit out and commissioning of a new building for the National Biologics Manufacturing Centre on Central Park, Darlington.
Contract value is estimated in the range of 拢10m to 拢25m.
The building will be three or four storeys with a footprint of approximately 4,000 m2, including all M&E services, laboratories, clean rooms and office, training and conferencing facilities.
Science minister David Willetts said: 鈥淭he new National Biologics Manufacturing Centre will significantly increase the UK鈥檚 manufacturing capability in biologics, keeping us ahead in the global race and strengthening the UK鈥檚 position as the location of choice for life sciences companies.鈥�
Steve Bates, chief executive of The BioIndustry Association, added: 鈥淭he National Biologics Manufacturing Centre will provide a valuable resource for the biologics manufacturing sector in the UK. The centre will help the UK capture more of the expanding global market in high value, high quality manufacture of biologic medicines. It is another key piece in the jigsaw in developing a supportive ecosystem for the bioscience sector alongside successful measures such as the Biomedical Catalyst, Patent Box and the Cell Therapy Catapult.鈥�
For details on the bidding process
Got a story? Email news@theconstructionindex.co.uk
